

1. AMENDMENTS TO THE CLAIMS (LISTING OF CLAIMS):

*This listing of claims will replace all prior versions and listings of claims in the application:*

1. (Currently Amended) A ribozyme that specifically cleaves an mRNA encoding an IGF-1 receptor polypeptide that causes or contributes to the disease, disorder, or dysfunction of a cell or a tissue of a mammalian eye, and wherein said ribozyme comprises the sequence of SEQ ID NO:100~~specifically cleaves an mRNA that comprises the sequence of SEQ ID NO:88.~~
- 2-3. (Canceled)
4. (Currently Amended) ~~A~~The ribozyme of claim 1, that ~~comprises~~consists of the sequence of SEQ ID NO:100.
- 5-13. (Canceled)
14. (Currently Amended) The ribozyme of claim 1 ~~or claim 4~~, wherein said ribozyme is a hammerhead ribozyme.
15. (Currently Amended) The ribozyme of claim 1 ~~or claim 4~~, wherein said ribozyme is a hairpin ribozyme.

16. (Currently Amended) A vector comprising a polynucleotide encoding the ribozyme of claim 1 ~~or claim 4~~, said polynucleotide operably linked to at least a first promoter element that directs expression of said polynucleotide in a mammalian cell.
17. (Original) The vector of claim 16, wherein said vector is a viral vector.
18. (Original) The vector of claim 17, wherein said viral vector is an adeno-associated viral vector.
19. (Original) The vector of claim 16, wherein said promoter element directs expression of said polynucleotide in a retinal cell.
20. (Original) The vector of claim 16, wherein said promoter element directs expression of said polynucleotide in a photoreceptor cell.
21. (Original) The vector of claim 16, wherein said promoter element directs expression of said polynucleotide in a rod or a cone cell.
22. (Currently Amended) The vector of claim 16, wherein said promoter element directs expression of said polynucleotide in a Mueller cell, or a retinal ~~pigment~~pigment epithelium cell.

23. (Original) The vector of claim 16, wherein said promoter element comprises a mammalian rod opsin promoter element.
24. (Original) The vector of claim 16, wherein said promoter element comprises a constitutive or an inducible promoter element.
25. (Currently Amended) A virus comprising the ribozyme of claim 1 ~~or claim 4~~, or a polynucleotide that encodes the ribozyme of claim 1 ~~or claim 4~~.
26. (Original) The virus of claim 25, wherein said virus is an adenovirus or an adeno-associated virus.
27. (Currently Amended) An adeno-associated viral vector comprising the ribozyme of claim 1 or claim 4, or a polynucleotide that encodes the ribozyme of claim 1 or claim 4.
28. (Original) The adeno-associated viral vector of claim 27, wherein said polynucleotide is operably linked to at least a first regulatory element that directs expression of said polynucleotide in a mammalian cell.
29. (Original) The adeno-associated viral vector of claim 28, wherein said regulatory element comprises a promoter that expresses said polynucleotide in a cell of a human eye.

30. (Currently Amended) A host cell that comprises:
- (a) the ribozyme of claim 1 ~~or claim 4~~;
  - (b) the vector of claim 16;
  - (c) the virus of claim 25; or
  - (d) the adeno-associated viral vector of claim 27.
31. (Original) The host cell of claim 30, wherein said cell is a mammalian host cell.
32. (Original) The host cell of claim 31, wherein said mammalian host cell is a human cell.
33. (Original) The host cell of claim 32, wherein said human cell is a retinal cell.
34. (Original) The host cell of claim 33, wherein said retinal cell is a photoreceptor cell.
35. (Original) The host cell of claim 34, wherein said retinal cell is a photoreceptor rod or cone cell.
36. (Currently Amended) A composition comprising:
- (a) the ribozyme of claim 1 ~~or claim 4~~;
  - (b) the vector of claim 16;
  - (c) the virus of claim 25; or

(d) the adeno-associated viral vector of claim 27.

37. (Original) The composition of claim 36, further comprising a pharmaceutical excipient.
38. (Original) The composition of claim 37, wherein said pharmaceutical excipient is suitable for ocular or subretinal administration to a mammalian eye.
39. (Original) The composition of claim 36, further comprising a lipid, a liposome, a nanoparticle, or a microsphere.
40. (Currently Amended) A kit comprising:
- (a) (i) the ribozyme of claim 1 ~~or claim 4~~;
  - (ii) the vector of claim 16;
  - (iii) the virus of claim 25; or
  - (iv) the adeno-associated viral vector of claim 27; and
  - (b) instructions for using said kit.
41. (Original) A kit comprising the composition of claim 36, and instructions for using said kit.
42. (Original) The kit of claim 41, further comprising device for delivering said composition to the eye, retina, or subretinal space of a mammal.

43. (Withdrawn – Currently Amended) A method for decreasing the amount of mRNA encoding ~~a selected~~ an IGF-1 receptor polypeptide in a retinal cell of a mammalian eye, comprising providing to said eye an amount of the composition of claim 36, and for a time effective to specifically cleave said mRNA in said cell, and thereby decrease the amount of IGF-1 receptor-specific mRNA in said cell.
- 44-52. (Canceled)
53. (Withdrawn – Currently Amended) A method for decreasing the amount of ~~a selected~~ IGF-1 receptor polypeptide in a cell or tissue of a mammalian eye, comprising providing to said eye an amount of the ribozyme of claim 1 ~~and for a time~~ effective to specifically decrease the amount of said ~~selected~~ IGF-1 receptor polypeptide in said cell or said tissue.
- 54-57. (Canceled).
58. (Previously Presented) A ribozyme that specifically cleaves an mRNA encoding a polypeptide that causes or contributes to the disease, disorder, or dysfunction of a cell or a tissue of a mammalian eye, wherein said ribozyme comprises the sequence of SEQ ID NO:100.

59. (Currently Amended) AThe ribozyme of claim 58, wherein said ribozyme that  
specifically cleaves an mRNA comprising the sequence of SEQ ID NO:88.